Proviral HIV-genome-wide and pol-gene specific Zinc Finger Nucleases: Usability for targeted HIV gene therapy
© Wayengera; licensee BioMed Central Ltd. 2011
Received: 26 May 2011
Accepted: 22 July 2011
Published: 22 July 2011
Infection with HIV, which culminates in the establishment of a latent proviral reservoir, presents formidable challenges for ultimate cure. Building on the hypothesis that ex-vivo or even in-vivo abolition or disruption of HIV-gene/genome-action by target mutagenesis or excision can irreversibly abrogate HIV's innate fitness to replicate and survive, we previously identified the isoschizomeric bacteria restriction enzymes (REases) AcsI and ApoI as potent cleavers of the HIV-pol gene (11 and 9 times in HIV-1 and 2, respectively). However, both enzymes, along with others found to cleave across the entire HIV-1 genome, slice (SX) at palindromic sequences that are prevalent within the human genome and thereby pose the risk of host genome toxicity. A long-term goal in the field of R-M enzymatic therapeutics has thus been to generate synthetic restriction endonucleases with longer recognition sites limited in specificity to HIV. We aimed (i) to assemble and construct zinc finger arrays and nucleases (ZFN) with either proviral-HIV-pol gene or proviral-HIV-1 whole-genome specificity respectively, and (ii) to advance a model for pre-clinically testing lentiviral vectors (LV) that deliver and transduce either ZFN genotype.
Methods and Results
First, we computationally generated the consensus sequences of (a) 114 dsDNA-binding zinc finger (Zif) arrays (ZFAs or ZifHIV-pol) and (b) two zinc-finger nucleases (ZFNs) which, unlike the AcsI and ApoI homeodomains, possess specificity to >18 base-pair sequences uniquely present within the HIV-pol gene (ZifHIV-polFN). Another 15 ZFNs targeting >18 bp sequences within the complete HIV-1 proviral genome were constructed (ZifHIV-1FN). Second, a model for constructing lentiviral vectors (LVs) that deliver and transduce a diploid copy of either ZifHIV-polFN or ZifHIV-1FN chimeric genes (termed LV- 2xZif HIV-pol F N and LV- 2xZif HIV-1 F N, respectively) is proposed. Third, two preclinical models for controlled testing of the safety and efficacy of either of these LVs are described using active HIV-infected TZM-bl reporter cells (HeLa-derived JC53-BL cells) and latent HIV-infected cell lines.
LV-2xZif HIV-pol F N and LV- 2xZif HIV-1 F N may offer the ex-vivo or even in-vivo experimental opportunity to halt HIV replication functionally by directly abrogating HIV-pol-gene-action or disrupting/excising over 80% of the proviral HIV DNA from latently infected cells.
-The global challenge of human immunodeficiency virus (HIV) infection
Human infection with the retrovirus-human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS) . Over a quarter a century since the description of the first clinical cases of AIDS, HIV/AIDS remains a global health challenge [2, 3]. There are now over 33 million people currently infected with HIV world-over, and 25 million lives have already been lost to AIDS. Despite the advent of a powerful regimen of highly active anti-retroviral therapy (HAART) to treat HIV/AIDS, HAART has its limitations [4, 5]. Specifically, while HAART targets actively replicating HIV, latent-HIV infection, particularly proviral HIV DNA integrated with resting CD4+ve cells, ultimately acts as a source of rebound viremia once treatment is stopped. Recent reports suggest that the reservoir of latent proviral HIV infection may extend beyond just the experimentally demonstrated CD4+ resting memory cells to include cells of the macrophage, natural-killer, dendrite, astrocyte and bone marrow progenitor lineages [6, 7]. Overall, in the absence of a vaccine that is 100% effective, novel strategies to tackle the unique challenge of latent HIV infection among patients on HAART are urgently sought . Although different mechanisms for the maintenance of reservoirs of latent HIV-infection have been advanced, the spectrum of emerging trial anti-HIV latency 'pro-drugs' is largely limited to those agents functioning via the awakening of resting host (CD4+ memory) cells; a strategy primarily meant to exorcise the latent provirus [5, 6]. Specifically, most of the trial anti-HIV latency pro-drugs (operating by non-specific stimulation of T cell receptors, TCR) function either globally via nuclear factor of activated T cells (NFAT) and protein C-kinase (PCK), or specifically via reductive oxidative substrates (ROS) and cytokines such as tumor necrotic factor-alpha (TNF-α) and interleukin-7 [8–11].
-The alternative option of directly disrupting or abolishing HIV gene expression
In 1999, I  first proposed the possibility of using the anti-phage DNA machinery inherent in bacteria -- the restriction modification (R-M) system (itself a primitive anti-viral immunity) - as a model for devising eukaryotic virus gene therapies. Over the past 10 years, I and colleagues [13, 14] have identified several bacterially-derived restriction enzymes with potential to cleave the DNA of human-infecting viruses, including frequency and site mapping of HIV-1, HIV-2 and several other SIV gene-cleavage using a proviral DNA model . The isoschizomeric bacterial restriction enzymes (REases) AcsI and ApoI have, for instance, specifically been found to possess high potency to cleave (slice or disrupt) the HIV pol gene (11 and 9 times in HIV-1 and -2, respectively) . Both enzymes, along with their third isoschizomer XapI, cleave at the palindromic site defined by the sequences 5'-RAATY-3'. Given the high incidence within the human host genome of site-specific units (palindromes) similar to those of the REases identified, matters of in-situ safety have proven a priority that is difficult to address, limiting our prior attack-models to the extracellular space [14, 16–21]. Specifically, because of the smaller sizes of phage genomes, bacteria evolve to select for R-M systems with small recognition sites (4-6 bp), since these sites occur more frequently in phages. However, this feature - a high incidence of palindromes - also renders the human genome highly susceptible to REase-activity. Therefore, a long-term goal in the field of R-M enzymatic therapeutics has been to generate synthetic restriction endonucleases with longer recognition sites specific only to the eukaryotic virus, by mutating or engineering existing enzymes.
Zinc Finger Nuclease technology and its applicability in antiviral gene therapy development
Zinc finger nucleases - ZFNs - which are artificial, hybrid restriction enzymes created by covalently linking a DNA-binding zinc finger (Zif) domain (composed of three to six finger-arrays) to the non-specific DNA cleavage domain (or simply FN) of the Flavobacterium Okeanokoites bacterial restriction endonuclease-FokI, have recently become a powerful tool for either primarily editing host genomes to halt viral infectivity, or secondarily targeting incoming or established viral genomes [22–30]. On the one hand, Perez et al. , using engineered ZFNs targeting human CCR5, previously demonstrated the establishment of HIV-1 resistance in CD4+ T cells through generation of a double-strand break (DSB) at predetermined sites in the CCR5 coding region upstream of the natural CCR5D32 mutation. More recently, Holmes et al.  demonstrated control of HIV-1 infection within NSG mice transplanted with human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeting CCR5. On the other hand, with the intent of disrupting incoming viral genomes, Gross et al. , have recently demonstrated homing (mega-) endonuclease-mediated inhibition of HSV-1 infection in cultured cells. Indeed, Cradick et al. had previously shown that zinc finger nucleases could equally offer a novel therapeutic strategy for targeting Hepatitis B Virus DNAs.
On the basis of the above advances in the field of ZFN technology, which permit the generation of synthetic restriction enzymes that are expressible within the human genome without causing functional or structural-genome toxicity, we postulated that synthetic zinc finger nucleases (ZFNs) with specificity to > 18 bp- palindromic sequence within the HIV-pol gene, unlike the 5'-RAATY-3' five-bp targeted by AcsI and ApoI, can specifically disrupt the HIV-pol gene with no toxicity-risk to the human genome[25–30]. Therapeutically, observing that the HIV-pol gene (~3,182 base pairs), which codes for the enzymes reverse transcriptase (RT), integrase and protease, is an indispensable section of the HIV genome for viral replication and survival, ex-vivo or even in-vivo disruption or abolition of HIV-pol should result in irreversible abrogation of HIV's innate fitness to replicate and survive . Alternatively, however, one may opt to target the entirety or most of the proviral genome for either disruption or excision. While inhibition of HIV replication in-vivo using small artificial molecules modified to harness the target DNA-binding mechanism inherent in zinc finger (ZF) domains as a strategy to repress HIV transcription has previously been reported by Segal et al. and Eberhardy et al. , respectively, ZFN-based disruption or abolition of HIV genes has yet to be reported. In other words, this work, unlike previous ZFN-based strategies aiming to cure HIV by targeting the host pathways, is an attempt to attack and modify the HIV pathway directly using ZFN technology.
The goal of this work was to identify and engineer, respectively, (i) HIV-pol gene and HIV-1 whole genome specific ZF arrays (ZFAs) and (ii) ZF-nucleases (ZFNs); as well as model construction and pre-clinical testing of lentiviral vectors (LVs) that deliver and transduce a diploid copy of either HIV-specific ZFN genotype.
Methods, results and discussion
Assembly of HIV-pol gene/HIV-1-proviral -dsDNA binding zinc finger arrays and construct of HIV-pol gene/HIV-1-proviral-dsDNA cleaving zinc finger nucleases
Five of the 114 ZFAs with binding specificity to sites within the SIV/HIV-pol gene
Zif array α-Helix (F1;F2;F3)
31 tGCAGAGTGTc 21
31 aCGTCTCACAg 21
RHQHLKL; RQDNLGR; QSNVLSR
50 aGAAGACAGGg 60
50 tCTTCTGTCCc 60
RRAHLLN; DRGNLTR; QSNNLNR
1515 gGCAGAAGCA g 1525
1515 cCGTCTTCGTc 1525
RGQELRR; QQTNLTR; QGNTLTR
1518 a GAAGCAGAA t 1528
1518 tCTTCGTCTTa 1528
QGSNLAR; QSTTLKR; QRNNLGR
3156 cGGAGAGGCTa 3166
3156 gCCTCTCCGAt 3166
NKQALDR; RQDNLGR; QANHLSR
The 2 ZFNs cleaving >18 bp sequences specifically within the HIV-pol gene
Zinc Finger Nuclease (ZFN)
Left Fn; triplet- α-Helix
Right Fn; triplet- α-Helix
-target HIV-pol-gene 5'
1063 gTTCTGCCTCAGGGATG GAAGGGGTC a 1089
1063 c AAGACGGAG TCCCTACCTTCCCCAGt 1089 1
-target HIV-pol-gene 3'
1871 cAACACCACCGCTAG TAAGATTAG t 1895
1871 g TTGTGGTGG CGATCATTCTAATCa 1895
Modeling the construct of lentiviral vectors for the specific delivery of a diploid copy of Zif-FN into CD4+ve cells
Third, lentiviral vectors (LVs)-by virtue of their unique ability to infect CD4 + cells inclusive of bone-marrow progenitor cell-lines, form an ideal vehicle for delivering and transducing the diploid copy of the SIV/HIV-pol gene/HIV-1 provirus-specific ZFNs (2x ZifHIV-polFN and 2x ZifHIV-1 FN) identified and cloned above[7, 40–42]. Over the past 10 years of our work with REases, LVs have emerged as potent and versatile vectors for ex vivo or in vivo gene transfer into dividing and non-dividing cells [15, 41]. The latter -- ability to infect non-dividing cells - presents a unique opportunity when targeting of proviral HIV DNA in resting CD4 + memory cells is considered [5, 6, 42]. Moreover, in conjunction with zinc-finger nuclease technology and HIV, LVs allow for site-specific gene correction or addition in predefined chromosomal loci where proviral HIV resides [5, 40, 43]. Therefore, although other vectors such as adenoviruses and γ-retroviral vectors can be used to deliver either HIV-specific ZFN genotype, the unique advantages offered by LVs plus several design improvements underscore the safety and efficacy of LVs, with significant implications for proviral HIV reservoir targeting gene therapy in humans . Specifically, robust phenotypic correction of diseases in mouse models has been achieved, paving the way toward the first clinical trials. LVs can deliver genes ex vivo into bona fide stem cells, particularly hematopoietic stem cells, allowing for stable transgene expression upon hematopoietic reconstitution. LVs can be pseudotyped with distinct viral envelopes that influence vector tropism and transduction efficiency . Nonetheless, our ultimate goal -- expressing proviral HIV DNA-specific Zif-FN within dividing and non-dividing CD4+ mammalian cell lines in-vivo - calls for specialized LV constructs. First, because LVs are derived from HIV-1, a human pathogen, it is critically important to ensure that the corresponding LV is replication-defective. The latest generation LV technology has several built-in safety features that minimize the risk of generating replication-competent wild type human HIV-1 recombinants. Typically, LVs are generated by trans-complementation whereby packaging cells are co-transfected with a plasmid containing the vector genome and the packaging constructs that encode only the proteins essential for LV assembly and function. Lentiviral plasmid vectors are in principle constructed by deleting 5 of the 9 wild type HIV genes, specifically vif, vpr, vpu, nef and tat, leaving behind a gap-pol-rev expression plasmid skeleton [42–44]. The rev gene, which binds to the rev-response protein exportin (RRE) to enable nuclear transport of the lentivirus, is often replaced by either a simian rev/RRE system or the Mason-Pfizer constitutive transport element (CTE), which exploit other intra-cisternal type A elements (IAPE) such as the RNA transport element (RTE) other than the rev/RRE complex to export lentivirus RNA out of the nucleus . Secondly, constructing the ultimate lentiviral plasmids encoding either the LV-2x ZifHIV-polFN or the LV-2x ZifHIV-1FN genotype should exploit the design advanced by Oh et al. comprising the HIV 5' long terminal repeat (LTR) fused with the Rous Sarcoma Virus (RSV) U5 region, and containing the phosphoglycerokinase (PGK) promoter required to drive the expression of a diploid copy of the hybrid bacterial, say the ZifHIV-polFN, chimeric gene (or simply LV-2xZifHIV-polFN particles). As a unique feature, a pair of splice donor (SD) and acceptor (SA) sites, the XbaI/NotI REase specificity sites separated by a 2A peptide, is required to enable PCR-based cloning of the diploid copy of the hybrid bacterial ZifHIV-polFN or ZifHIV-1FN gene into the pHRSVcPGKnls backbone to yield the either LV-2x ZifHIV-polFN or LV-2x ZifHIV-1FN transfer vector plasmid or particles as final products. Such multicistronic constructs, in which several proteins are encoded by a single messenger RNA, are commonly used in genetically engineered animals . Although the use of an internal ribosomal entry site (IRES) was previously favored for multicistronic constructs, Tichas et al.  recently demonstrated the efficient use of the 2A peptide for bicistronic expression and co-translational cleavage in transgenic mice. The final LV-particles can then be produced recombinantly in large amounts by the known transient triple-plasmid transfection of 293T cells [40, 42, 44, 46, 47]. In practice, it is necessary that plasmids are at this stage evaluated for their gene-delivery and transduction potential using the protocols previously described by Oh et al. and Mátrai et al., but tailored to ZFNHIV-pol before their packaging. Ultimately, packaging cells are transfected with the lentiviral vector plasmid and three helper (packaging) constructs encoding Gag, Pol, Rev, and VSV-G. Only the vector contains the packaging sequence Ψ, whereas the packaging constructs are devoid of Ψ. The LV is flanked by the 5' and 3' LTR sequences that have promoter/enhancer activity and are essential for the correct expression of the full-length vector transcript. The LTRs also play important roles in reverse transcription and integration of the vector into the target cell genome. Overall, self-inactivating (SIN) LTR sequences that contain a partial deletion (Δ), Woodchuck post-transcriptional regulatory element (WPRE), central polypurine tract (cPPT), and Rev responsive element (RRE) are used. Assembled vector particles can then be harvested from the supernatant and, if required, subjected to further purification and concentration. Packaging LVs encoding different envelope genes only serves to allow for production of distinct LV pseudotypes with different tropisms .
3. Testing the efficacy and safety of the lentiviral vectors delivering and transducing SIV/HIV-pol-gene specific, ZFN
Thirdly and finally, preclinical models for controlled testing of the safety and efficacy of LV- 2xZifHIV-polFN or LV- 2xZifHIV-1FN may be devised using either active HIV-infected TZM-bl reporter cells (HeLa-derived JC53-BL cells that express high levels of CD4, CXCR4, and CCR5, and contain reporter cassettes for luciferase and β-galactosidase, both driven by the HIV-1 long terminal repeat); or latent-HIV-infected J-Lat cell lines that harbor a full-length HIV-1 genome that is transcriptionally competent and is integrated within actively transcribed cellular genes, but is inhibited at the transcriptional level [41, 48]. Note, however, that the J-Lat cells may not offer us an appropriate model of latency, and Oh et al.  have recently established two novel cell lines latently infected with HIV-1 by limiting dilution cloning of resting A3.01 cells infected with HIV-1. These represent an alternative and better option to J-Lat cells for studying the molecular mechanisms of viral latency and development of anti-reservoir therapy of HIV-1 infection. In the first instance, I propose the innoculation of a single-parent culture of TZM-bl reporter cells on Dulbecco medium (DMEM), which is subsequently divided into two: a test-daughter (td) sample and a control-daughter (cd) sample. The td-sample is modified by transfection with, say, LV- 2x ZifHIV-polFN to express ZifHIV-polFN (the efficiency of ZifHIV-polFN expression must be tested here, say by ELISA assays); the cd sample is left untreated. At time zero (T0), both td and cd samples are infected with HIV at infectious doses of 0.1, 0.2, 0.3 million particles per unit, after which they are cultured for a further 24-36 hours. The efficacy for abolition or disruption of HIV-pol gene expression can be measured by studying the level of abrogation in HIV's innate fitness to replicate and survive in-vivo, through measuring the level of chemiluminescence from the reporter cassettes for luciferase and β-galactosidase (expected to be diminished in td sample once ZifHIV-polFN is highly efficacious, since reporter cassettes are driven by the HIV-1 long terminal repeat). This initial experiment essentially offers a model for testing the primary prevention of HIV infection by LV-2x ZifHIV-polFN (a preventive vaccine mode). Safety should be evaluated by assaying and comparing levels of inflammatory cytokines, apoptotic DNA ladders, and targeted sequencing of proviral HIV integration hot spots (say via PCR amplification of the HIV-LTR) within the TZM-bl reporter cells in td relative to cd- samples (no significant differences are expected for a safe profile). In the second alternative scenario, using either J-Lat or the Oh et al.  cell lines that offer us an in vitro model of HIV-1 latency, we can devise a model for testing the potency of LV-2x ZifHIV-polFN towards the end-goal of HIV therapeutic cure and latent provirus eradication . Specifically, a parent culture of J-Lat or Oh et al.  cells maintained on DMEM is divided into a td- and cd- sample. As above, the td- sample is transfected with (say) LV-2x ZifHIV-polFN at time zero (T0) and the extent of ZifHIV-polFN expression again measured, say by ELISA-assays, while the cd-sample is left untreated. The efficacy of LV-2x ZifHIV-polFN in irreversibly abrogating the innate fitness of the HIV provirus to replicate within latently infected cells through the abolition or disruption of HIV-pol gene/genome action can be measured by studying the level of fluorescence (a marker of latent provirus, and one expected to be low in the td-sample once ZifHIV-polFN are expressed and efficacious); following the addition of agents that exorcise proviral HIV-DNA [5, 8–11]. This assay should be facilitated by ensuring that the latent provirus integrated in the Oh et al.  cell lines, as in J-Lat cells, also includes the GFP gene . The latter would provide us with a fluorescent marker of HIV-1 transcriptional activity. Again, safety here can be evaluated by assaying and comparing levels of inflammatory cytokines, apoptotic DNA ladders, and targeted sequencing of proviral HIV integration hot spots (say via PCR amplification of HIV-LTR) within the J-Lat or Oh et al.  cells in td relative to cd- samples (no significant differences are expected in respect of safety).
4. Availability: Databases and software
The ZFN consortium CoDA-ZiFiT-ZFA/ZFN software and algorithms used are available at the following url: http://www.zincfingers.org/scientific-background.htm
The NCBI gene database hosting the HIV-pol gene and HIV-1 whole genome are available at the following url:
I report here SIV/HIV-pol gene and HIV-1 whole genome specific zinc finger nucleases, which are proposed for use towards targeted HIV gene therapy. Specifically, because of the notoriety and promiscuousness of HIV at evading previous therapeutic and vaccine attempts, we - building on the bacterial R-M enzymatic machinery as a primitive anti-viral model and prior work identifying bacterial REases against SIV/HIV genomes - postulated that ex-vivo or even in-vivo disruption of viral gene action or excision of over 80% of proviral HIV DNA from within infected cells can irreversibly inactivate both active and latent virus [4–7, 12–14]. The SIV/HIV-specific bacterial REases previously identified towards this purpose also target short palindromic targets present within the human genome and thereby carry the risk for toxicity . Now, however, in the wake of advances in zinc finger technology, I have assembled 114 ZFAs (Figure 1, Table 1, and Additional file 2) and constructed 2 ZFNs (Figure 2, Table 2, and Additional file 2) with unique specificity to >18 bp sequences present only within the SIV/HIV pol gene. In addition, another 15 ZFNs were constructed that target and cleave within the >18 bp sequences present only within the proviral DNA of the whole HIV-1 genome (see Figure 3 for graphic distribution of the cleavage sites and pattern. For details of the latter, see additional file 3). It is therefore speculated that lentiviral vectors carrying either genotype (LV-2xZif HIV-pol F N or LV- 2xZif HIV-1 F N ) may offer the ex-vivo or even in-vivo experimental opportunity to halt HIV replication functionally by directly-either abrogating HIV-pol gene action or excising over 80% of proviral HIV dsDNA from latently infected cells [40, 42].
Several potential limitations are contingent on the above proposition that readers should take into account, as these may require addressing before this technology is moved from the lab into human trials. First, the possibility of genome toxicity, though minimized by the shift from our prior REase model to hybrid ZFN prototypes, remains and underlines the rationale for conducting the above suggested genome-safety profiling [14, 18, 36]. In this regard, perhaps the HIV-pol gene or HIV-1 whole genome specificity of those 3-zinc finger nucleases identified in this study may benefit from further modular enhancements towards 4, 5, or 6 finger arrays . The specificity of such multi-finger proteins can also be enhanced by in-vitro optimization using a bacteria-one hybrid (B1H) or yeast-one-hybrid (Y1H) system . Moreover, modifications to the cleavage domain in order to generate a hybrid capable of functionally interrogating the ZFN dimer interface so as to prevent homodimerization, while still enhancing the efficiency of cleavage, are equally possible . Second, clinical trails of lentiviral vectors are still limited globally, a fact that may hinder the global use of the technology, particularly within the low and middle income countries most affected by the HIV epidemic . Outweighing these potential shortcomings, though, is that LV technology has greatly improved over the past decade [40, 42]. Moreover, LVs offer us the added user-friendly advantage that they may be directly administered to patients via intravenous (IV) or intra-osseous (IO) in-vivo routes and yet still effect a therapeutically adequate gene delivery and transduction for HIV preventive or therapeutic purposes (vaccines); though this may be less than the up-to-17% achieved by ex-vivo routes [28, 42]. Overall, for purposes of targeting latent proviral HIV reservoir, the likelihood that in-vivo delivered LVs would ever find and effectively transduce a latently-infected cell with the diploid copy of the ZFN remains to be established, considering that those latently infected cells might be circulating randomly all around the body in the blood [5, 6]. Perhaps experiments to evaluate the efficiency and extent of in-vivo LV-delivery using humanized mice, as Wilen et al. recently did, and fluorescent labeled LVs, may suffice here. Until such experiments establish these in-vivo LV-delivery routes as adequate, however, the already proven ex-vivo alternative remains most viable [27, 28, 43]. Alternatively, since only about 1 in 1,000,000 memory T-cells are latently infected in the body, they are hard targets to hit by LVs delivered directly in-vivo, and more strategies may be required, either to enhance the above-presented model or act as completely novel in-vivo ZFN-delivery vehicles [42, 43]. Also, the efficiency of targeted mutagenesis by LVs delivered in this manner, which would have to be extremely high in order to affect enough cells to be useful, remains questionable yet relevant to know, since even a small residual reservoir of cells carrying the provirus would be sufficient to restart a systemic infection [5, 23–28]. One may, however, counter this reasoning by arguing that neither all nor any resting memory CD+ cells need to be modified by LVs in order to halt the buildup of a re-infection functionally. Specifically, once the newly emerging active (non-resting) CD4+ve cells from the progenitor cell-lines are all resistant, any new HIV particles will have no active CD4+ cells to infect and propagate in. In addition, there could be several proviral HIV integration sites in a single CD4+ cell genome, unlike the loci for host gene targets such as CCR5, and that presents another challenge and yet an opportunity for LVs to wipe out HIV efficaciously from within infected cells[5, 6, 27, 28, 42]. Despite all the above reservations surrounding the efficiency of gene delivery associated with in-vivo relative to ex-vivo routes, we can maintain that further exploration of novel LV designs for in-vivo delivery may circumvent these obstacles and allow for a wider usability of these HIV gene- or genome-specific ZFNs as therapeutics, particularly since this would eliminate the need for the costly process of autologous bone marrow pre-harvest, ZFN-engineering and subsequent transplantation [12, 13, 28]. That would make these treatments easily accessible to people within resource-limited settings where HIV is most prevalent and the former science is lacking. Induction of a type I interferon response that reduces LVs availability is possible, but this is likely to be very minimal among persons living with HIV or AIDS who are in late stages of immunosuppression, while use of steroid or non-myeloablative preparative regimens may be required for those not yet immunocompromised [50, 51]. Third, HIV is notorious for evolving mutations that lead to resistance to drugs, and ZFNs are no exceptions. For instance, it is possible that HIV, by evolving single base substitutions, may evade the specificity of REases [4, 5]. Nonetheless, we note that because many mutations leading to resistance to HAART are single point mutations, and ZFN-resistance mutations may need to accrue in >18 bp, such cumulative substitutions are likely to be selectively disfavored since the progeny virus possessing them is phenotypically disadvantaged [4, 52]. Last but not least, many lentiviral vector plasmids exploit a gap-pol core as the expression plasmid-skeleton, which raises the possibility that the LV-plasmid's pol-gene component may itself be targeted by our HIV specific Zinc Finger Nucleases, particularly ZifHIV-polFN. To eliminate this possibility, perhaps the design for the ZifHIV-polFN genotype carrying LV-plasmids should exploit constructs recently described by Oh et al., which comprise just the HIV 5' long terminal repeat fused with the Rous Sarcoma Virus U5 region and use the phosphoglycerokinase (PGK) promoter to drive the expression of the diplod copy of ZifHIV-polFN. Only the cis-acting DNA element known as the central polypurine tract sequence (or cppt) from the pol gene is included 5' to PGK [42, 46].
In conclusion, on the basis of the hypothesis that in-vivo abolition of HIV gene action or disruption/excision of over 80% of proviral HIV DNA can abrogate HIV's innate fitness to replicate and survive, I engineer HIV-pol gene and HIV-1 whole genome specific Zinc Finger Nucleases (ZFNs) and advance the protocol for constructing and pre-clinically testing lentiviral vectors that deliver and transduce a diploid copy of either ZFN genotype (LV-2xZif HIV-pol F N or LV- 2xZif HIV-pol F N ). LV-2xZif HIV-pol F N and LV- 2xZif HIV-1 F N may offer the ex-vivo or even in-vivo experimental opportunity to halt HIV replication functionally by directly abrogating HIV-pol gene action or disrupting/excising over 80% of proviral HIV dsDNA from latently infected cells.
No specific funding was received towards this work. I thank Dr. Henry Kajumbula (MakCHS, Microbiology-Uganda) and Prof. Wilson Byarugaba (KIU-WC, Biochemistry-Uganda) for keen collaboration on previous related work.
The SIV/HIV-pol gene NCBI genomic context reference is NC_001870.1; >gi|9629914:1714-4893; while the HIV-1 whole genome NCBI ref is |NC_001802.1|; gene identity >gi|9629357|.
- Gallo RC, Montagnier L: The Discovery of HIV as the Cause of AIDS. N Engl J Med. 2003, 24: 2283-2285. 349View ArticleGoogle Scholar
- CDC: Pneumocystis carinii pneumonia among persons with hemophilia A. MMWR. 1982, 31: 365-7.Google Scholar
- UNAIDS & World Health Organization. AIDS Epidemic Update: 2009, GenevaGoogle Scholar
- Wayengera M, Kajumbula H, Byarugaba W: Harnessing pharmacogenomics to tackle resistance to the "Nucleoside Reverse Transcriptase Inhibitor" backbone of highly active antiretroviral therapy in resource limited settings. Open AIDS Journal. 2008, 2: 78-81. 10.2174/1874613600802010078.PubMed CentralView ArticlePubMedGoogle Scholar
- Wayengera M: Targeting persistent HIV: Where and how, if possible?. HIV & AIDS Review. 2011, 10: 8-View ArticleGoogle Scholar
- Onafuwa-Nuga A, McNamara LA, Collins KL: Towards a cure for HIV: the identification and characterization of HIV reservoirs in optimally treated people. Cell Res. 2011, 20 (11): 1185-1187.View ArticleGoogle Scholar
- The Council of the Global HIV Vaccine Enterprise: The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Nature Med. 2010, 16: 981-989. 10.1038/nm0910-981.View ArticleGoogle Scholar
- Antoni BA, Rabson AB, Kinter A, Bodkin M, Poli G: NF-kappa B dependent and -independent pathways of HIV activation in a chronically infected T cell line. Virology. 1994, 202: 684-694. 10.1006/viro.1994.1390.View ArticlePubMedGoogle Scholar
- Contreras X, Barboric M, Lenasi T, Peterlin BM: HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog. 2007, 3 (10): e146-10.1371/journal.ppat.0030146.PubMed CentralView ArticleGoogle Scholar
- Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, Giri S, Nagarkatti P, Nagarkatti M, Chauhanet A: Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner. PLoS ONE. 2010, 5 (6): e11160-10.1371/journal.pone.0011160.PubMed CentralView ArticlePubMedGoogle Scholar
- Choudhary SK, Margolis DM: Curing HIV: Pharmacologic Approaches to Target HIV-1 Latency. Annu Rev Pharmacol Toxicol. 2011, 51: 397-418. 10.1146/annurev-pharmtox-010510-100237.PubMed CentralView ArticlePubMedGoogle Scholar
- Wayengera M: HIV and Gene Therapy: The proposed [R-M enzymatic] model for a gene therapy against HIV. Makerere Med J. 2003, 38: 28-30.Google Scholar
- Wayengera M, Kajumbula H, Byarugaba W: Identification of restriction endonuclease with potential ability to cleave the HSV-2 genome: inherent potential for biosynthetic versus live microbicides. BMC Theor Biol Med Model. 2008, 5: 18-10.1186/1742-4682-5-18.View ArticleGoogle Scholar
- Wayengera M: Why bacteria derived R-M nucleic enzymatic peptides are efficient therapeutic molecules for use in the design and development of novel HIV therapeutic molecules. Afr J Biotechnol. 2008, 7 (12): 1791-1796.Google Scholar
- Wayengera M, Kajumbula H, Byarugaba W: Frequency and site mapping of HIV-1/SIVcpz, HIV-2/SIVsmm and Other SIV gene sequence cleavage by various bacteria restriction enzymes: Precursors for a novel HIV inhibitory product. Afr J Biotechnol. 2007, 6 (10): 1225-1232.Google Scholar
- Wayengera M: A Recombinant lactobacillus strain producing restriction enzymes that cleave proviral HIV DNA may offer a novel Vagino-cervical mucosal exogenous live Microbicide strategy for preventing HIV transmission among high-risk women. Afr J Biotechnol. 2007, 6 (15): 1750-1756.Google Scholar
- Wayengera M: PREX-1979: Modeling the first ever prototype of could be a 5th generation of Microbicides for preventing HIV infection among high-risk women. Afr J Biotechnol. 2007, 6 (10): 1221-1224.Google Scholar
- Wayengera M: Pre-Integration gene slicing (PRINT-GSX) as an alternate or complimentary gene therapy modem to RNA interference. J Appl Biol Sci. 2008, 1 (2): 56-63.Google Scholar
- Wayengera M: Diverting primary HIV entry and replication to vaginal commensal lactobacillus expressing R-M nucleic enzymatic peptides with potent activity at cleaving proviral DNA as a novel HIV live microbicide strategy. Microbicide- New Delhi, India. 2008, Abs-10Google Scholar
- Wayengera M: Preparing for a Phase 1 Preclinical trial of VRX-SMR: a Lentiviral Vector transduced with restriction enzymes cleaving HIV proviral DNA as a therapeutic vaccine: Opportunities and Challenges. Vaccine Congress -Amsterdam, Netherlands. 2007, 24OR-Google Scholar
- Wayengera M: xREPLAB: A recombinant lactobacillus strain producing restriction enzymes with potent activity against HIV proviral DNA as a Live Microbicide Strategy. AIDS vaccine- Washington, Seattle. 2007, P05-01.Google Scholar
- Kim YG, Cha J, Chandrasegaran S: Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA. 1996, 93 (3): 1156-1160. 10.1073/pnas.93.3.1156.PubMed CentralView ArticlePubMedGoogle Scholar
- Cathomen T, Joung JK: Zinc-finger nucleases: the next generation emerges. Mol Ther. 2008, 16 (7): 1200-1207. 10.1038/mt.2008.114.View ArticlePubMedGoogle Scholar
- Guo J, Gaj T, Barbas CF: Directed Evolution of an Enhanced and Highly Efficient FokI Cleavage Domain for Zinc Finger Nucleases. Journal of Molecular Biology. 2010, 400 (1): 96-10.1016/j.jmb.2010.04.060.PubMed CentralView ArticlePubMedGoogle Scholar
- Durai S, Mani M, Kandavelou K, Wu J, Porteus MH, Chandrasegaran S: Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res. 2005, 33 (18): 5978-5990. 10.1093/nar/gki912.PubMed CentralView ArticlePubMedGoogle Scholar
- Porteus MH, Carroll D: Gene targeting using zinc finger nucleases. Nat Biotechnol. 2005, 23 (8): 967-73. 10.1038/nbt1125.View ArticlePubMedGoogle Scholar
- Perez E, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, Guschin DY, Rupniewski I, Waite AJ, Carpenito C, Carroll RG, Orange JS, Urnov FD, Rebar EJ, Ando D, Gregory PD, Riley JL, Holmes MC, June CH: Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. 2008, 26 (7): 808-816. 10.1038/nbt1410.PubMed CentralView ArticlePubMedGoogle Scholar
- Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM: Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010, 28 (8): 839-847. 10.1038/nbt.1663.PubMed CentralView ArticlePubMedGoogle Scholar
- Grosse S, Huot N, Mahiet C, Arnould S, Barradeau S, Clerre DL, Chion-Sotinel I, Jacqmarcq C, Chapellier B, Ergani A, Desseaux C, Cédrone F, Conseiller E, Pâques F, Labetoulle M, Smith J: Meganuclease-mediated Inhibition of HSV1 Infection in Cultured Cells. Mol Ther. 2011, 19 (4): 694-702. 10.1038/mt.2010.302.PubMed CentralView ArticlePubMedGoogle Scholar
- Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP: Zinc-finger Nucleases as a Novel Therapeutic Strategy for Targeting Hepatitis B Virus DNAs. Mol Ther. 2010, 18 (5): 947-954. 10.1038/mt.2010.20.PubMed CentralView ArticlePubMedGoogle Scholar
- Segal DJ, Goncalves J, Eberhardy SR, Swan CH, Torbett BE, Li X, Barbas CF: Attenuation of HIV-1 Replication in Primary Human Cells with a Designed Zinc Finger Transcription Factor. J Biochem. 2004, 279 (15): 14509-14519.Google Scholar
- Eberhardy SR, Goncalves J, Coelho S, Segal DJ, Berkhout B, Barbas CF: Inhibition of Human Immunodeficiency Virus Type 1 Replication with Artificial Transcription Factors Targeting the Highly Conserved Primer-Binding Site. J Virol. 2006, 80 (6): 2873-2883. 10.1128/JVI.80.6.2873-2883.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Dreier B, Segal DJ, Barbas CF: Insights into the molecular recognition of the 5 '-GNN-3 ' family of DNA sequences by zinc finger domains. J Mol Biol. 2000, 303 (4): 489-502. 10.1006/jmbi.2000.4133.View ArticlePubMedGoogle Scholar
- Mandell JG, Barbas CF: Zinc finger tools: custom DNA-binding domains for transcription factors and nucleases. Nucleic Acids Res. 2006, 34 (Sp.Iss. SI): W516-W523.PubMed CentralView ArticlePubMedGoogle Scholar
- Sander JD, Zaback PZ, Joung JK, Voytas DF, Dobbs D: Zinc Finger Targeter (ZiFiT): an engineered zinc finger/target site design tool. Nucleic Acids Research. 2007, 35: W599-605. 10.1093/nar/gkm349.PubMed CentralView ArticlePubMedGoogle Scholar
- Sander JD, Dahlborg EJ, Goodwin MJ, Cade L, Zhang F, Cifuentes D, Curtin SJ, Blackburn JS, Thibodeau-Beganny S, Qi Y, Pierick CJ, Hoffman E, Maeder ML, Khayter C, Reyon D, Dobbs D, Langenau DM, Stupar RM, Giraldez AJ, Voytas DF, Peterson RT, Yeh JR, Joung JK: Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat Methods. 2011, 8 (1): 67-69. 10.1038/nmeth.1542.PubMed CentralView ArticlePubMedGoogle Scholar
- Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD: Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010, 11 (9): 636-646. 10.1038/nrg2842. S,View ArticlePubMedGoogle Scholar
- Doyon Y, Vo TD, Mendel MC, Greenberg SG, Wang J, Xia DF, Miller JC, Urnov FD, Gregory PD, Holmes MC: Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods. 2011, 8 (1): 74-79. 10.1038/nmeth.1539.View ArticlePubMedGoogle Scholar
- Herrmann F, Garriga-Canut M, Baumstark R, Fajardo-Sanchez E, Cotterell J, Minoche A, Himmelbauer H, Isalan M: p53 Gene Repair with Zinc Finger Nucleases Optimised by Yeast 1-Hybrid and Validated by Solexa Sequencing. PLoS ONE. 2011, 6 (6): e20913-10.1371/journal.pone.0020913.PubMed CentralView ArticlePubMedGoogle Scholar
- Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D: In vivo gene delivery and stable transduction of non dividing cells by a lentiviral vector. Science. 1996, 272: 263-267. 10.1126/science.272.5259.263.View ArticlePubMedGoogle Scholar
- Jordan A, Bisgrove D, Verdin E: HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. Embo J. 2003, 22: 1868-1877. 10.1093/emboj/cdg188.PubMed CentralView ArticlePubMedGoogle Scholar
- Mátrai J, Chuah MK, VandenDriessche T: Recent advances in lentiviral vector development and applications. Mol Ther. 2010, 18 (3): 477-490. 10.1038/mt.2009.319.PubMed CentralView ArticlePubMedGoogle Scholar
- Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, Rebar EJ, Sherrill-Mix SA, Patro SC, Secreto AJ, Jordan APO1, Lee G, Kahn J, Aye PP, Bunnell BA, Lackner AA, Hoxie JA, Danet-Desnoyers GA, Bushman FD, Riley JL, Gregory PD, June CH, Holmes MC, Doms RM: Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases. PLoS Pathog. 2011, 7 (4): e1002020-10.1371/journal.ppat.1002020.PubMed CentralView ArticlePubMedGoogle Scholar
- Oh T, Bajwa A, Jia G, Park F: Lentiviral vector design using alternative RNA export elements. Retrovirology. 2007, 4: 38-10.1186/1742-4690-4-38.PubMed CentralView ArticlePubMedGoogle Scholar
- Trichas G, Begbie J, Srinivas S: Use of the viral 2A peptide for bicistronic expression in transgenic mice. BMC Biol. 2008, 6: 40-10.1186/1741-7007-6-40.PubMed CentralView ArticlePubMedGoogle Scholar
- Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D: Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998, 72: 9873-9880.PubMed CentralPubMedGoogle Scholar
- Wodrich H, Schambach A, Krausslich HG: Multiple copies of the Mason-Pfizer monkey virus constitutive RNA transport element lead to enhanced HIV-1 Gag expression in a contextdependent manner. Nucleic Acids Res. 2000, 28: 901-910. 10.1093/nar/28.4.901.PubMed CentralView ArticlePubMedGoogle Scholar
- Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E: Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 2009, 5 (6): e1000495-10.1371/journal.ppat.1000495.PubMed CentralView ArticlePubMedGoogle Scholar
- Oh YT, Kim KC, Hong KJ, Lee HS, Jang DH, Lee JS, Choi SY, Kim SS, Choi BS: Establishment of novel cell lines latently infected with human immunodeficiency virus 1. Acta Virol. 2011, 55 (2): 155-9. 10.4149/av_2011_02_155.View ArticlePubMedGoogle Scholar
- Brown BD, Sitia G, Annoni A, Hauben E, Sergi LS, Zingale A, Roncarolo MG, Guidotti LG, Naldini L: In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood. 2007, 109 (7): 2797-805.PubMedGoogle Scholar
- Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, Shaffer J, Preffer FI, Ding R, Sharma V, Fishman JA, Dey B, Ko DS, Hertl M, Goes NB, Wong W, Williams WW, Colvin RB, Sykes M, Sachs DH: HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008, 358 (4): 353-361. 10.1056/NEJMoa071074.PubMed CentralView ArticlePubMedGoogle Scholar
- Wayengera M: Identity of zinc finger nucleases with specificity to Herpes simplex virus type II genomic DNA: novel HSV-2 vaccine/therapy precursors. Theor Biol Med Model. 2011, 8 (1): 23-10.1186/1742-4682-8-23.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.